Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Neutrophil-targeting drug seeks first approval in an inflammatory lung disease
Insmed’s DPP1 inhibitor brensocatib could become the first drug to secure an approval for bronchiectasis, and is in trials for other inflammatory diseases.
The FDA is weighing the regulatory fate of Insmed’s DPP1 inhibitor brensocatib for bronchiectasis. An approval for the oral small-molecule protease inhibitor would provide a much-needed targeted therapy for this debilitating, chronic respiratory disorder, which affects over 1 million people worldwide. It would also be a first approval for an inhibitor of DPP1, also known as cathepsin C, an enzyme made by neutrophils to bolster their inflammatory activity.
